A personalized vaccine developed by Moderna and Merck reduced the recurrence of melanoma in a large, late-stage trial, raising expectations for treating the deadliest form of skin cancer and showing the promise of the embattled mRNA technology.
Source: [Bloomberg Markets](https://www.bloomberg.com/news/videos/2026-08-19/moderna-merck-revive-mrna-hopes-with-melanoma-success)